Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Vet Comp Oncol. 2010 Jun;8(2):103-11. doi: 10.1111/j.1476-5829.2010.00211.x.
This prospective study evaluated the efficacy and safety of hydroxyurea (HU) in dogs with measurable mast cell tumours (MCTs). Dogs were treated with HU at 60 mg kg(-1)per os q24h for 14 days then 30 mg kg(-1) q24h thereafter or until MCT recurrence. Forty-six dogs were enrolled. The overall response rate was 28%. Two dogs had a complete response (CR) for 256 and 448 days, respectively. Eleven dogs had a partial response for a median duration of 46 days (range, 28-189 days). Grade 2 to 4 neutropenia occurred in eight dogs and grade 4 thrombocytopenia in two. Grade 3-4 anaemia occurred in seven dogs; overall, there was a significant decrease in haematocrit after treatment with HU. The median drop in haematocrit was 10%. This study demonstrated that HU has activity in the treatment of MCTs with mild anaemia being the primary adverse event.
本前瞻性研究评估了羟基脲 (HU) 在可测量肥大细胞瘤 (MCT) 犬中的疗效和安全性。HU 以 60 mg/kg 口服，每 24 小时一次，治疗 14 天，然后以 30 mg/kg 口服，每 24 小时一次，直至 MCT 复发。共纳入 46 只犬。总体缓解率为 28%。2 只犬获得完全缓解（CR），持续时间分别为 256 天和 448 天。11 只犬获得部分缓解，中位缓解持续时间为 46 天（范围为 28-189 天）。8 只犬出现 2-4 级中性粒细胞减少症，2 只犬出现 4 级血小板减少症。7 只犬出现 3-4 级贫血症；总体而言，HU 治疗后血红蛋白显著下降。血红蛋白下降的中位数为 10%。本研究表明，HU 在治疗 MCT 方面具有活性，轻度贫血是主要的不良事件。
Zotero 插件